Cannabidiol Reverses Deficits in Hippocampal LTP in a Model of Alzheimer’s Disease

Neurochemical Research

Volumn 44, Issue 3, 2019, Pages 703-713

  Hughes, Blathnaid ^a   Herron, Caroline E ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

5HT 1A; Adenosine A 2A; Alzheimer s disease; Beta amyloid peptide; Cannabidiol; CB 1 R; Long term potentiation; PPAR

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 CHLORO 5 NITROBENZANILIDE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE A2A RECEPTOR; AMYLOID BETA PROTEIN[1-42]; CANNABIDIOL; CANNABINOID 1 RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OLIGOMER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SEROTONIN 1A RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; PEPTIDE FRAGMENT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CANNABIS SATIVA; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL SLICE; LONG TERM POTENTIATION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION; ANIMAL; C57BL MOUSE; HIPPOCAMPUS; METABOLISM; NERVE CELL PLASTICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CANNABIDIOL; HIPPOCAMPUS; LONG-TERM POTENTIATION; MICE, INBRED C57BL; NEURONAL PLASTICITY; PEPTIDE FRAGMENTS; PIPERIDINES; PYRAZOLES;

EID: 85044385733     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-018-2513-z     Document Type: Article

References (58)

1. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 12(10):383–388
2. Holtzman DM et al (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 97(6):2892–2897
3. Mc Donald JM et al (2010) The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia. Brain 133(5):1328–1341
4. Enya M et al (1999) Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Aβ) dimer in the cortex during aging. Am J Pathol 154(1):271–279
5. Roher AE et al (1996) Morphology and toxicity of Aβ-(1–42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer’s disease. J Biol Chem 271(34):20631–20635
6. Vigo-Pelfrey C et al (1993) Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem 61(5):1965–1968
7. Bliss TV, Collingridge GL, Morris RG (2014) Synaptic plasticity in health and disease: introduction and overview. Philos Trans R Soc Lond B Biol Sci 369(1633):20130129
8. swe /PS1dE9 mice. J Alzheimers Dis 39(2):315–329
9. Costello DA, O’Leary DM, Herron CE (2005) Agonists of peroxisome proliferator-activated receptor-gamma attenuate the Aβ-mediated impairment of LTP in the hippocampus in vitro. Neuropharmacology 49(3):359–366
10. Lauren J et al (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457(7233):1128–1132
11. Freir DB et al (2011) Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat Commun 2:336
12. Nicoll AJ et al (2013) Amyloid-beta nanotubes are associated with prion protein-dependent synaptotoxicity. Nat Commun 4:2416
13. swe /PS1∆E9 mice. Psychopharmacology 231(15):3009–3017
14. Iuvone T et al (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 89(1):134–141
15. Krishnan S, Cairns R, Howard R (2009) Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev 2: CD007204
16. Booz GW (2011) Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med 51(5):1054–1061
17. Martin-Moreno AM et al (2011) Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease. Mol Pharmacol 79(6):964–973
18. Esposito G et al (2006) Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 399(1–2):91–95
19. Esposito G et al (2011) Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS ONE 6(12):e28668
20. 1 receptor. Br J Pharmacol 172(20):4790–4805
21. Vallee A et al (2017) Effects of cannabidiol interactions with Wnt/beta-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer’s disease. Acta Biochim Biophys Sin (Shanghai) 49(10):853–866
22. Ledgerwood CJ et al (2011) Cannabidiol inhibits synaptic transmission in rat hippocampal cultures and slices via multiple receptor pathways. Br J Pharmacol 162(1):286–294
23. 1A receptors. Br J Pharmacol 159(1):122–128
24. 1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 156(1):181–188
25. 1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology 199(2):223–230
26. Ribeiro A et al (2012) Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor. Eur J Pharmacol 678(1–3):78–85
27. 2A adenosine receptor. Invest Ophthalmol Vis Sci 49(12):5526–5531
28. O’Sullivan SE et al (2009) Time-dependent vascular actions of cannabidiol in the rat aorta. Eur J Pharmacol 612(1–3):61–68
29. McPartland JM, Glass M, Pertwee RG (2007) Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol 152(5):583–593
30. 2 receptor agonists in vitro. Br J Pharmacol 150(5):613–623
31. Bisogno T et al (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134(4):845–852
32. Carrier EJ, Auchampach JA, Hillard CJ (2006) Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 103(20):7895–7900
33. 1A receptor antagonist, WAY-100635. Eur J Pharmacol 281(1):81–88
34. 2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 138(7):1207–1209
35. Leesnitzer LM et al (2002) Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41(21):6640–6650
36. 2+ levels. J Neurosci 29(7):2053–2063
37. Shankar GM et al (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27(11):2866–2875
38. 1 region of rat hippocampal slices. Br J Pharmacol 124(1):93–100
39. Thomas BF et al (1998) Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 285(1):285–292
40. 1 receptor function on glutamate axon terminals by endogenous adenosine acting at A1 receptors. J Neurosci 30(2):545–555
41. 2 receptor pharmacology of three plant cannabinoids: ∆9-tetrahydrocannabinol, cannabidiol and ∆9-tetrahydrocannabivarin. Br J Pharmacol 153(2):199–215
42. 2 receptors. Front Pharmacol 8:744
43. de Mendonça A, Ribeiro JA (2001) Adenosine and synaptic plasticity. Drug Dev Res 52(1–2):283–290
44. 2A receptor-mediated hyperexcitability in the hippocampus. Hippocampus 25(5):566–580
45. Hasko G, Cronstein BN (2004) Adenosine: an endogenous regulator of innate immunity. Trends Immunol 25(1):33–39
46. 2 and adenosine receptors. Neurobiol Dis 37(2):434–440
47. 1 . Neuropharmacology 49(5):660–668
48. Karl T et al (2012) The therapeutic potential of the endocannabinoid system for Alzheimer’s disease. Expert Opin Ther Targets 16(4):407–420
49. 1 receptor blockade. Eur J Pharmacol 477(3):219–225
50. Heneka MT, Landreth GE (2007) PPARs in the brain. Biochim Biophys Acta 1771(8):1031–1045
51. Bouhlel MA et al (2007) PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 6(2):137–143
52. (1–42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β. Nat Neurosci 14(5):545–547
53. Peineau S et al (2007) LTP inhibits LTD in the hippocampus via regulation of GSK3β. Neuron 53(5):703–717
54. da Silva VK et al (2014) Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection. Mol Neurobiol 49(1):222–233
55. Fagherazzi EV et al (2012) Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders. Psychopharmacology 219(4):1133–1140
56. Esposito G et al (2006) The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J Mol Med (Berl) 84(3):253–258
57. Cabrero A, Laguna JC, Vazquez M (2002) Peroxisome proliferator-activated receptors and the control of inflammation. Curr Drug Targets Inflamm Allergy 1(3):243–248
58. Inestrosa NC et al (2005) Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp Cell Res 304(1):91–104